The American Diabetes Association (ADA) has recently released the Standards of Care in Diabetes—2024, offering comprehensive guidelines for managing type 1, type 2, gestational diabetes, and prediabetes based on the latest research. The update includes recommendations on obesity drugs, screening practices, diabetes technology, and the use of teplizumab.
Notable changes involve managing obesity, screening for heart failure and peripheral arterial disease, and guidance on teplizumab and new obesity medications. The guidelines also focus on hypoglycemia prevention, screening for nonalcoholic fatty liver disease, and attention to diabetes-specific risk factors for fracture. Emphasis is placed on mastering diabetes technology and addressing the possible association between COVID-19 and new-onset type 1 diabetes. Other updates cover immunization, cultural sensitivity, psychosocial screening, and the importance of diabetes technology.
Download the guideline: Link
For associated resources: Link
Enjoy Free Shipping for Limited Time only, visit POM Marketplace now!
Login or Sign Up for an account today!
* Access to POM Marketplace is available to qualified healthcare professionals only.
Disclaimer: The information provided on this website is intended for educational purposes only, and while we strive for accuracy, POMConnect assumes no liability for errors or omissions. The opinions expressed in this article are those of the author and do not necessarily reflect the views or opinions of POMConnect or its affiliated organizations. The content should not be considered a substitute for professional medical advice. Always consult with a qualified healthcare provider regarding any medical concerns. POMConnect not endorse specific treatments or external websites linked from this site. POM Marketplace is accessible exclusively to qualified healthcare professionals. Any unauthorized access or use by individuals who do not meet this criteria is prohibited.
